4
Changes in Ownership
CytomX Therapeutics, Inc. Filed Acc 0001140361-17-045018
Chief Financial Officer sold 2,500 shares at $20.58 ($51,450)
- Chief Financial Officer acquired 163 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| RAY DEBANJAN Chief Financial Officer | 2017-11-30 | Grant or award | +163 | $12.15 | $1,980 | 12,289 | D |
| RAY DEBANJAN Chief Financial Officer | 2017-12-01 | Sale | −2,500 | $20.58 | $51,450 | 9,789 | D |
| Open-market sales · 2,500 sh · avg $20.58 · $51,450 | |||||||
Loading xslF345X03/doc1.xml…